GenVec develops gene therapy products and has a lead to treat Heart Disease that is now in Ph II clinicals. The lead is a modified Human adenovirus non-RCA (that means it can't replicate) vector that carries an expression cassette for VEGF121, an angiogenic gene. The trade mark name is "BIOBYPASS".
GENVEC today has filed an S-1 with the SEC.
genvec.com
If the PhII clinicals come out good, this could be a BIG winner. Remember, that potentially therapeutic genes are available; it's the vehicle to deliver the genes to therapeutic locations that's the challenge.
If GenVec can demonstrate delivery and persistence of gene expression in this model, there will be many more theraputic applications to follow.
The Lead under writter is JP Morgan. -they don't have a habit of making bad bets... ever. |
